- Home
- EARN vs FENC Comparison
EARN vs FENC Comparison
Compare EARN & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EARN
- FENC
- Stock Information
- Founded
- EARN 2012
- FENC 1996
- Country
- EARN United States
- FENC United States
- Employees
- EARN N/A
- FENC N/A
- Industry
- EARN Real Estate Investment Trusts
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EARN Real Estate
- FENC Health Care
- Exchange
- EARN Nasdaq
- FENC Nasdaq
- Market Cap
- EARN 189.7M
- FENC 234.9M
- IPO Year
- EARN 2013
- FENC 2001
- Fundamental
- Price
- EARN $5.09
- FENC $8.20
- Analyst Decision
- EARN Buy
- FENC Strong Buy
- Analyst Count
- EARN 2
- FENC 2
- Target Price
- EARN $5.88
- FENC $13.50
- AVG Volume (30 Days)
- EARN 356.7K
- FENC 70.8K
- Earning Date
- EARN 11-19-2025
- FENC 11-12-2025
- Dividend Yield
- EARN 18.86%
- FENC N/A
- EPS Growth
- EARN N/A
- FENC N/A
- EPS
- EARN N/A
- FENC N/A
- Revenue
- EARN $35,893,000.00
- FENC $33,302,000.00
- Revenue This Year
- EARN N/A
- FENC N/A
- Revenue Next Year
- EARN $15.93
- FENC $64.79
- P/E Ratio
- EARN N/A
- FENC N/A
- Revenue Growth
- EARN 43.30
- FENC N/A
- 52 Week Low
- EARN $4.33
- FENC $3.96
- 52 Week High
- EARN $6.99
- FENC $9.92
- Technical
- Relative Strength Index (RSI)
- EARN 35.22
- FENC 40.00
- Support Level
- EARN $5.10
- FENC $8.21
- Resistance Level
- EARN $5.40
- FENC $9.16
- Average True Range (ATR)
- EARN 0.09
- FENC 0.43
- MACD
- EARN 0.01
- FENC -0.06
- Stochastic Oscillator
- EARN 20.52
- FENC 9.86
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.